Skip to main content
Caplight Logo









ImmunoBiome Inc.

ImmunoBiome Inc.

Private
PohangHealthcare & Life Scienceshttps://www.immunobiome.co.kr/

Last Round

Series B

Jan 1, 2022

Total Funding Raised

$23.81M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

ImmunoBiome Inc. is a biotechnology company that develops microbiome-targeted therapeutics and live biotherapeutic products (LBPs) for incurable diseases such as cancer, autoimmune disorders, and autism spectrum disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Infrastructure

Keywords

microbiome therapeuticslive biotherapeutic productsLBPgut microbiomedrug discoveryautoimmune disease treatmentmicrobiome drugbioinformaticsAI drug discoveryprecision medicinebiotech R&Dgut bacteriamicrobiome diagnosticstherapeutic pipelinepreclinical development

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

ImmunoBiome Inc. Comparables

Compare ImmunoBiome Inc. with similar companies based on industry and business-model similarity.

ImmunoBiome Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Enterobiome Inc.
87%
Exeliom Biosciences
81%
PharmaBiome
80%

ImmunoBiome Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BJan 1, 2022
Series ASep 1, 2020
Pre SeedDec 1, 2019
SeedJul 1, 2019

ImmunoBiome Inc. Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 3, 2026

    Open roles increased to 398, 1895% of headcount.

  • Jul 26, 2026

    Monthly visitors grew 192% MoM, from 386 to 1.1K.

ImmunoBiome Inc. Filings

Explore SEC and related filing metadata, where available.

ImmunoBiome Inc. filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about ImmunoBiome Inc.'s valuation, stock price, and market status.

Is ImmunoBiome Inc. a public or private company?

ImmunoBiome Inc. is a private company.

What is the current stock price of ImmunoBiome Inc.?

ImmunoBiome Inc. is a private company with no public stock price. No recent secondary market data is available.

How much is ImmunoBiome Inc. worth (valuation)?

Valuation information for ImmunoBiome Inc. is not publicly available.

Can I buy ImmunoBiome Inc. stock?

ImmunoBiome Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was ImmunoBiome Inc.'s last funding round?

ImmunoBiome Inc.'s most recent funding round was Series B on January 1, 2022.

Who are the main investors in ImmunoBiome Inc.?

Key investors in ImmunoBiome Inc. include Korea Investment Partners.

Will ImmunoBiome Inc. IPO soon?

No public IPO plans have been announced for ImmunoBiome Inc..

How can I track ImmunoBiome Inc. secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor ImmunoBiome Inc.'s secondary market activity and sign up for updates.

Firmographic Details

HeadquartersPohang
Employee Range21
Year Founded2019
Last FundingJan 1, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?